Beckman Coulter Inc. 6/21/10

Department of Health and Human Services	Public Health Service Food and Drug Administration
	10903 New Hampshire Avenue Building 66 Silver Spring, MD 20993

WARNING LETTER

VIA FEDERAL EXPRESS

Beckman Coulter, Inc.

c/o Mr. Scott T. Garrett

President/CEO

200 S. Kraemer Blvd.

Brea, California 92821, USA

JUN 21, 2010

Dear Mr. Garrett:

The Food and Drug Administration (FDA) has learned that your firm is marketing the AccuTnI on the Access Immunoassay System in the United States (U.S.) without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).

Under section 201(h) of the Act, the AccuTnI on the Access Immunoassay System is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or function of the body, 21 U.S.C. 321(h). The Act requires that manufacturers of devices that are not exempt obtain marketing approval or clearance for their products from the FDA before they may offer them for sale. This helps protect the public health by ensuring that new devices are shown to be both safe and effective or substantially equivalent to other devices already legally marketed in this country for which approval is not required.

A review of the documentation provided by your firm reveals that you have made significant modifications that may affect the performance of your product and have not obtained marketing approval or clearance before offering your modified product for sale, which is a violation of the law. Specifically, AccuTnI on the Access Immunoassay System is adulterated under section 501(f)(l)(B) of the Act, 21 U.S.C. 351(f)(l)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. 352(o), because you did not notify the agency of your intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81 (b). The kind of information you need to submit in order to obtain approval or clearance for your device is described on the Internet at http://www.fda.gov/cdrh/devadvice/3122.html. The FDA will evaluate the information you submit and decide whether your product may be legally marketed.

You should take prompt action to correct these deviations. Failure to promptly correct these deviations may result in regulatory action being initiated by the Food and Drug Administration without further notice. These actions include, but are not limited to, seizure, injunction, and/or

civil money penalties. Also, Federal agencies are advised of the issuance of all Warning Letters about devices so that they may take this information into account when considering the award of contracts.

Please let this office know in writing what steps you have taken to correct the problem within fifteen (15) working days from the date you received this letter. We also ask that you explain how you plan to prevent this from happening again. If you need more time, let us know why and when you expect to complete your correction. Please direct your response or any questions you may have to:

James L. Woods, W066, Office 5688

Deputy Director

Patient Safety and Product Quality

Office of Invitro Diagnostic Device Evaluation and Safety

Center for Devices and Radiological Health

10903 New Hampshire Avenue

Silver Spring, MD 20993

Finally, you should understand that there are many FDA requirements pertaining to the manufacture and marketing of devices. This letter pertains only to the issue of premarket review for your device and does not necessarily address other obligations you have under the law.

Sincerely yours,

/s/

Alberto Gutierrez, PhD

Director

Office of In-Vitro Diagnostics

Evaluation and Safety

Center for Devices and Radiological Health

-